{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-093920","form_type":"8-K","ticker":"EVMN","cik":"0002044725","company_name":"Evommune, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.109022+00:00","generated_at":"2026-05-15T20:01:44.341012+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Evommune reports Q4/FY2025 net loss $28.3M/$68.9M; positive EVO301 Ph2a data; $125M raise","bullets":["Q4 net loss $28.3M; FY net loss $68.9M vs $66.8M prior year. Revenue $13.0M FY (Maruho deal). Cash $216.7M at Dec 31, 2025.","Positive Phase 2a POC data for EVO301 in atopic dermatitis: met primary endpoint, 33% placebo-adjusted EASI reduction at week 12 after 2 doses.","EVO756 Phase 2b top-line data expected 2Q26 for CSU, 2H26 for AD; Phase 2b in migraine to start mid-2026.","Closed $125M private placement in Feb 2026; cash runway extended through 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-093920","json":"https://secwatch.observer/filing/0001193125-26-093920.json","markdown":"https://secwatch.observer/filing/0001193125-26-093920.md","text":"https://secwatch.observer/filing/0001193125-26-093920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526093920/0001193125-26-093920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526093920/evmn-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T20:01:44.341012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}